Clinical DevelopmentArcus is set to begin their first Phase 3 registration trial with the combination therapy compared to monotherapy, indicating progress in clinical development.
Clinical EfficacyArcus's combination data at ASCO exceeded expectations, suggesting a stronger future performance for the stock.
Financial StabilityArcus ended the quarter with $1 billion in cash, cash equivalents, and marketable securities, which they expect will fund operations through three pivotal readouts.